Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

By M. Talim. Diabetes Care, 2007

943 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/b3524a0967e71002c1df0eb388e8e987ea5b24af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Pathology and Forensic Medicine

Citations in the corpus

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, neutral): “Given that most patients with T2DM have NAFLD (8–12) and many are at risk for NASH even if they have normal liver aminotransferase levels (6, 9, 13, 14), it is surprising that few trials have focused on this population.”
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? (2018, background): “5%.(58) Substantial evidence also indicates that people with T2DM are at high risk of developing NASH, and a twofold to fourfold higher risk of developing serious liver-related complications (cirrhosis, liver failure and HCC).”
Non-alcoholic fatty liver disease: the mist gradually clears. (2008, background): “A recent study of unselected patients with T2DM reported that the prevalence of cardiovascular, cerebrovascular and peripheral vascular disease was significantly greater in those with NAFLD than in those without independent of the individual components of the metabolic syndrome [10].”
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease (2013, positive): “This decrease is correlated to histological features of NAFLD independent of age, sex, BMI, HOMA-insulin resistance, and other metabolic syndrome (MS) components [20,79].”
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity (2011, background): “in diabetic and obese, and 90% in morbidly obese patients (4,5), while NASH affects 3% of the general adult population, 25% – 30% of obese and diabetic, and 35% of morbidly obese individuals (6,7).”
INCREASED HEPATIC SYNTHESIS AND DYSREGULATION OF CHOLESTEROL METABOLISM IS ASSOCIATED WITH THE SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE (2012, background): “Several studies have also linked NAFLD to an increased risk of cardiovascular disease, a leading cause of death in this population (Brea et al., 2005; Hanley C et al., 2005; Targher et al., 2007; Villanova et al., 2005).”
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss (2022, background): “A study of patients with T2DM found a higher prevalence of peripheral vascular, coronary and cerebrovascular diseases in subjects with NAFLD than without, with coronary, cerebrovascular and peripheral vascular disease was greater among those with NAFLD than among those without this disease, aside fr”
NAFLD: a multisystem disease. (2015, result): “Similarly, in a large outpatient-cohort study of patients with T2DM, the prevalence of coronary, cerebrovascular and peripheral vascular disease was greater among those with NAFLD than among those without this disease, independently of traditional CVD risk factors, medication use and diabetes-relate”